Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Fibrin clot structure and mechanics associated with specific oxidation of methionine residues in fibrinogen.

Weigandt KM, White N, Chung D, Ellingson E, Wang Y, Fu X, Pozzo DC.

Biophys J. 2012 Dec 5;103(11):2399-407. doi: 10.1016/j.bpj.2012.10.036.

2.

Reduced plasminogen binding and delayed activation render γ'-fibrin more resistant to lysis than γA-fibrin.

Kim PY, Vu TT, Leslie BA, Stafford AR, Fredenburgh JC, Weitz JI.

J Biol Chem. 2014 Oct 3;289(40):27494-503. doi: 10.1074/jbc.M114.588640. Epub 2014 Aug 15.

3.

Fibrinogen and fibrin.

Weisel JW.

Adv Protein Chem. 2005;70:247-99. Review.

PMID:
15837518
4.

Nonclottable fibrin obtained from partially reduced fibrinogen: characterization and tissue plasminogen activator stimulation.

Procyk R, Medved L, Engelke KJ, Kudryk B, Blombäck B.

Biochemistry. 1992 Mar 3;31(8):2273-8.

PMID:
1540582
5.

Conversion of fibrinogen to fibrin: mechanism of exposure of tPA- and plasminogen-binding sites.

Yakovlev S, Makogonenko E, Kurochkina N, Nieuwenhuizen W, Ingham K, Medved L.

Biochemistry. 2000 Dec 26;39(51):15730-41.

PMID:
11123898
6.

Clot penetration and fibrin binding of amediplase,a chimeric plasminogen activator (K2 tu-PA).

Rijken DC, Barrett-Bergshoeff MM, Jie AF, Criscuoli M, Sakharov DV.

Thromb Haemost. 2004 Jan;91(1):52-60.

PMID:
14691568
7.

Fibrinogen and fibrin structure and functions.

Mosesson MW.

J Thromb Haemost. 2005 Aug;3(8):1894-904. Review.

8.

[Inhibition of the process of Glu-plasminogen activation by tissue activator with fibrin, DDE-complex, and D-dimer using alpha-2-antiplasmin].

Hrynenko TV, Zadorozhna MB, Platonova TM, Volkov HL.

Ukr Biokhim Zh (1999). 2005 Sep-Oct;77(5):45-51. Ukrainian.

PMID:
16846069
9.

Unfavorably altered fibrin clot properties in patients with active rheumatoid arthritis.

Kwasny-Krochin B, Gluszko P, Undas A.

Thromb Res. 2010 Jul;126(1):e11-6. doi: 10.1016/j.thromres.2010.04.007. Epub 2010 May 14.

PMID:
20471669
10.

Fibrin Formation, Structure and Properties.

Weisel JW, Litvinov RI.

Subcell Biochem. 2017;82:405-456. doi: 10.1007/978-3-319-49674-0_13. Review.

PMID:
28101869
11.

Searching for differences between fibrinogen and fibrin that affect the initiation of fibrinolysis.

Doolittle RF.

Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):181-9. Review.

PMID:
18673232
12.

Structural effects of methionine oxidation on isolated subdomains of human fibrin D and αC regions.

Burney PR, White N, Pfaendtner J.

PLoS One. 2014 Jan 27;9(1):e86981. doi: 10.1371/journal.pone.0086981. eCollection 2014.

13.

Fibrinogen gamma-chain splice variant gamma' alters fibrin formation and structure.

Cooper AV, Standeven KF, Ariëns RA.

Blood. 2003 Jul 15;102(2):535-40. Epub 2003 Mar 27.

14.

Fibrin-mediated plasminogen activation.

Nieuwenhuizen W.

Ann N Y Acad Sci. 2001;936:237-46. Review.

PMID:
11460481
15.

[Binding of alpha-2-antiplasmin with fibrinogen/fibrin and their fragments independent of factor XIII].

Zadorozhna MB, Hrynenko TV, Iusova OI, Volkov HL.

Ukr Biokhim Zh (1999). 2004 Sep-Oct;76(5):71-7. Ukrainian.

PMID:
16100900
17.

The structure and biological features of fibrinogen and fibrin.

Mosesson MW, Siebenlist KR, Meh DA.

Ann N Y Acad Sci. 2001;936:11-30. Review.

PMID:
11460466
19.

Rapid dissociation of platelet-rich fibrin clots in vitro by a combination of plasminogen activators and antiplatelet agents.

Lam SC, Dieter JP, Strebel LC, Taylor TM, Muscolino G, Feinberg H, Le Breton GC.

J Pharmacol Exp Ther. 1991 Dec;259(3):1371-8.

PMID:
1762085
20.

The role of conformational domain lability of fibrinogen molecule in the processes of fibrin formation and fibrinolysis.

Rozenfel'd MA, Leonova VB, Biryukova MI.

Dokl Biochem Biophys. 2006 May-Jun;408:165-8. No abstract available.

PMID:
16913421

Supplemental Content

Support Center